Monoclonal immunoglobulin-derived vaccine against multiple myeloma - First clinical experience;Využiti̇ monoklonálního imunoglobulinu k přípravě protinádorové vakcíny u nemocných s mnohočetným myelomem - První zkušenosti z klinické studie

Klinicka Onkologie

Volumn 17, Issue 2, 2004, Pages 64-67

  Buchler T ^a,b   Hanak L ^b   Smejkalova J ^b   Kovarova L ^b   Krejci M ^a   Adam, Z ^a   Michalek J ^b   Penka, M ^b   Vorlicek J ^a   Hajek R ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b Oddeleni Klinicke Hematologie   (Czech Republic)

Author keywords

Clinical study; Idiotype; Immunotherapy; Multiple myeloma; Vaccination

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; DEXAMETHASONE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; PARAPROTEIN; THALIDOMIDE;

ARTICLE; CANCER CENTER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IMMUNE RESPONSE; MULTIPLE MYELOMA; SIDE EFFECT; TARGET CELL; TUMOR CELL;

EID: 2442675253     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995; 345: 1016-20.
2. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996; 92: 840-6.
3. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459-66.
4. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16.
5. Büchler T, Hájek R. Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations. Med Oncol 2002;19:213-8.
6. Büchler T, Musilová R, Kovářová L, Hájek R. Vakcíny v léčbě mnohoč etného myelomu. Klinická onkologie 2002; 15 (Suppl): 44-7.
7. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673-83.
8. Reichardt VL, Okada CY, Liso A. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93:2411-9.
9. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000; 6:621-7.
10. Hájek R, Žáčková D, Büchler T, Penka M, Krahulcová E, Kořístek Z, Vinklá rková J, Adler J, Janovská E, Indrák K, Faber E, Doubek M, Klabusay M, Oltová A, Kuglík P, Bourková L, Dušek L, Mareschová I, Mayer J, Vorlíček J. Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration. Med Oncol 2003;20:69-76.
11. Musilová R, Táborská E, Bourková L, Büchler T, Hanák L, Kovářová L, Novotná H, Penka M, Hájek R. Příprava a použití nádorového antigenu z patologického imunoglobulinu pro pacienty s mnohočetnym myelomem. Transfuze a hematologie dnes 2002; 8: 91-5.
12. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opinion Oncol 2000; 12: 564-73.
13. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-8
14. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999; 48:118-22.
15. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59:3340-5.
16. Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Craig D, Arani RB, Schlom J, LoBuglio AF. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999;5:2330-7.
17. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, Black HC, Goldfield M. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979;69:1247-50.
18. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979;140:234-8.